UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 124

Sortiert nach

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1356-1384

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes

Diabetes care, 2022-05, Vol.45 (5), p.1170-1176

2022

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Scientific reports, 2019-01, Vol.9 (1), p.566-566, Article 566

2019

Link zum Volltext

Verfügbarkeit prüfen

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.54-62

2019

Link zum Volltext

Verfügbarkeit prüfen

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Targeted oncology, 2017-12, Vol.12 (6), p.709-718

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

Cancer medicine (Malden, MA), 2016-09, Vol.5 (9), p.2567-2578

2016

Link zum Volltext

Verfügbarkeit prüfen

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer

Scientific reports, 2022-05, Vol.12 (1), p.9054-9054, Article 9054

2022

Link zum Volltext

Verfügbarkeit prüfen

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Frontiers in immunology, 2022-09, Vol.13

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Current treatment options in oncology, 2023-12, Vol.24 (12), p.1802-1814

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular therapeutic targets in non-small cell lung cancer

Expert review of anticancer therapy, 2020-08, Vol.20 (8), p.647-661

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21062-e21062

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9138-TPS9138

2022

Link zum Volltext

Verfügbarkeit prüfen

Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8536-8536

2018

Link zum Volltext

Verfügbarkeit prüfen

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations

Expert opinion on pharmacotherapy, 2022-09, Vol.23 (14), p.1569-1575

2022

Link zum Volltext

Verfügbarkeit prüfen

The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use

Translational cancer research, 2016-10, Vol.5 (S4), p.S632-S635

2016

Link zum Volltext

Verfügbarkeit prüfen

Cyclin-dependent kinase inhibitors for the treatment of lung cancer

Expert opinion on pharmacotherapy, 2020-05, Vol.21 (8), p.941-952

2020

Link zum Volltext

Verfügbarkeit prüfen

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Cancer cell, 2023-02, Vol.41 (2), p.304-322.e7

2023

Link zum Volltext

Verfügbarkeit prüfen

Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin

Journal of cancer survivorship, 2015-06, Vol.9 (2), p.252-259

2015

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC

Clinical lung cancer, 2019-07, Vol.20 (4), p.e495-e503

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Clinical lung cancer, 2024-03, Vol.25 (2), p.128-134

2024

Link zum Volltext

Verfügbarkeit prüfen

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2023-09, Vol.41 (27), p.JCO2301261-4432

2023

Link zum Volltext

Verfügbarkeit prüfen

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

Journal of clinical oncology, 2024-02, Vol.42 (5), p.562-570

2024

Link zum Volltext

Verfügbarkeit prüfen

The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8510-8510

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.35-41

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(123)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(66)
Humans
(50)
Oncology
(29)
Animals
(22)
Female
(21)
Middle Aged
(13)
Physical Sciences
(13)
Adult
(11)
Aged
(11)
Lung Neoplasms - Pathology
(11)
Male
(10)
Mice
(10)
Risk Factors
(10)
Science & Technology - Other Topics
(10)
Immunology
(9)
Lung Neoplasms - Drug Therapy
(9)
Medicin Och Hälsovetenskap
(9)
Multidisciplinary Sciences
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Molecular therapeutic targets in non-small cell lung cancer

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC)

A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab

Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients

Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations

The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use

Cyclin-dependent kinase inhibitors for the treatment of lung cancer

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin

Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC

A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Suchergebnisse filtern